The Division has developed innovative approaches to radioimmunotherapy of cancer using novel targeting molecules. This research has contributed to the funding of Ovarian and Breast Cancer Specialized Programs of Research Excellence (SPORE) at UAB by the National Cancer Institute, and funding to the Cancer Center from the Avon Products Research Foundation for breast cancer research. In addition, the Division of Radiation Biology has been in the forefront of research into the treatment of cancer in experimental models with a combination of gene therapy and radiation therapy. This has resulted in a SPORE in Brain Cancer and grants and contracts from the National Cancer Institute, the Department of Energy, and the Department of Defense, with emphasis on colon, ovarian, and prostate cancer. Another significant finding was unlabeled antibody against epidermal growth factor receptor resulted in increased sensitivity of head and neck cancer to radiation. This was translated into a clinical phase I trial in head and neck cancer at UAB. A phase III trial testing this new combination therapy with UAB as the lead institution showed significantly increased local tumor control and survival in patients with head and neck cancer. This resulted in FDA approval of this therapy for patients with head and neck cancer.
The Division has also played a central role in the evaluation of death receptor antibodies for cancer therapy, and has received support for this research from Daiichi Sankyo through the UAB/Sankyo Program for Rheumatic Diseases and Cancer Research in the Arthritis and Musculoskeletal Diseases Center, and from the Pancreatic Cancer SPORE and Accelerated Brain Cancer Cure, Inc.
The Division is also carrying out research on antibody-drug conjugates for targeted cancer therapy and the use of adenoviral vectors to produce single chain antibodies against epidermal growth factor receptor as radiosensitizing agents. Other replicative and non-replicative vectors containing genes that produce chemosensitization and radiosensitization are being studied. Additional studies are being conducted with novel radiosensitizers. Thus, very innovative and clinically relevant research is being carried out in the Division of Radiation Biology.